20-F/A: Cellectis S.A. Files Amendment No. 1 to 20-F Annual Report to Correct Administrative Errors in Auditor Consents
20-F/A Amendment
Cellectis S.A. files an amendment to its 20-F annual report to correct administrative errors in the consents provided by KPMG SA and Ernst & Young et Autres.
Summary
- Cellectis S.A. is filing Amendment No. 1 to its Annual Report on Form 20-F for the fiscal year ended December 31, 2024.
- The amendment is solely to provide updated Exhibit 15.1 (Consent of KPMG SA) and Exhibit 15.2 (Consent of Ernst & Young et Autres) to correct administrative errors.
- The error in KPMG SA's consent was the inadvertent omission of the conformed signature.
- The error in Ernst & Young et Autres' consent was the inclusion of an incorrect date.
- The updated consents are included with this Amendment No. 1.
- The amendment includes new certifications by the company's principal executive officer and principal financial officer.
- The company has not modified or updated any other disclosures made in the original Form 20-F in this amendment.
Sentiment
Score: 7
Explanation: The document is a routine amendment to correct administrative errors, indicating a neutral to slightly positive sentiment as the company is taking steps to ensure accurate reporting.
Positives
- The company is proactively correcting administrative errors in its filings.
- Updated certifications from the CEO and CFO are included.
Future Outlook
The amendment does not provide any forward-looking statements; it only addresses corrections to the original filing.
Industry Context
This filing is a routine amendment to correct administrative errors, which is a standard practice in financial reporting. It doesn't significantly impact the broader industry context.
Stakeholder Impact
- The correction of administrative errors in the auditor consents ensures the accuracy of financial reporting, which is important for stakeholders including shareholders and potential investors.
Key Dates
| Date | Description |
|---|---|
| 2011-01-10 | Exclusive Patent License Agreement between Regents of the University of Minnesota and Cellectis S.A. |
| 2012-05-24 | First Amendment to the Exclusive Patent License Agreement between Regents of the University of Minnesota and Cellectis S.A. |
| 2014-04-01 | Second Amendment to the Exclusive Patent License Agreement between Regents of the University of Minnesota and Cellectis S.A. |
| 2014-10-23 | Patent & Technology License Agreement between Ohio State Innovation Foundation and Cellectis S.A. |
| 2015-03-10 | Date of various filings related to share plans and deposit agreements. |
| 2015-12-16 | Third Amendment to the Exclusive Patent License Agreement between Regents of the University of Minnesota and Cellectis S.A. |
| 2016-12-02 | Filing related to the 2016 Stock Option Plan. |
| 2018-01-09 | Filing related to the 2017 Stock Option Plan. |
| 2018-04-13 | Filing related to the Free Share 2018 Plan. |
| 2018-10-05 | Filings related to the 2018 Stock Option Plan and BSA Plan. |
| 2019-03-06 | License, Development and Commercialization Agreement between Les Laboratoires Servier and Cellectis S.A. |
| 2019-03-08 | License Agreement between Allogene Therapeutics, Inc. and Cellectis S.A. |
| 2019-04-25 | Date of various filings related to license agreements. |
| 2020-03-04 | Amendment No. 1 to License, Development and Commercialization Agreement between Les Laboratoires Servier and Cellectis S.A. |
| 2020-03-05 | Filing related to the amendment of the Servier agreement. |
| 2021-03-04 | Filing related to the Second Free Share 2018 Plan. |
| 2021-03-29 | Sales Agreement between Cellectis S.A. and Jefferies LLC. |
| 2021-08-05 | Filings related to the 2021 Stock Option Plan and 2021 Free Shares Plan. |
| 2022-10-06 | Filings related to the 2022 Stock Option Plan and 2022 Free Shares Plan. |
| 2022-11-04 | Fourth Amendment to the Exclusive Patent License Agreement between Regents of the University of Minnesota and Cellectis S.A. |
| 2022-12-28 | Credit Facility Agreement between the European Investment Bank and Cellectis S.A. |
| 2023-01-04 | Amendment No. 1 to the Sales Agreement between Jefferies LLC and Cellectis S.A. |
| 2023-03-30 | Subscription Agreement for Warrants to be issued by Cellectis S.A. |
| 2023-08-07 | Filings related to the 2023 Stock Option Plan and 2023 Free Shares Plan. |
| 2023-11-01 | Joint Research and Collaboration Agreement and Initial Investment Agreement between Cellectis S.A. and AstraZeneca. |
| 2023-11-09 | Date of various filings related to agreements with AstraZeneca. |
| 2023-11-14 | Subsequent Investment Agreement between AstraZeneca Holdings B.V. and Cellectis S.A. |
| 2024-05-27 | 2024 Employees Change of Control Plan. |
| 2025-01-15 | Filings related to the 2024 Stock Option Plan and 2024 Free Shares Plan. |
| 2025-03-13 | Date of auditor reports and consents. |
| 2025-03-14 | Date of the original Form 20-F filing and this amendment. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.